510(k) Premarket Notification and Substantial Equivalence

1. Key takeaways

The 510(k) is a premarket notification submitted to the FDA that must be filed at least 90 days before the sponsor intends to begin commercial distribution of the device. The central question examined during 510(k) review is not whether the sponsor can prove that the product is safe and effective in absolute terms. Instead, the sponsor must demonstrate that the device is substantially equivalent (SE) to a legally marketed predicate device. Until the FDA issues its substantial equivalence decision letter, commercial distribution of the device is not permitted under any circumstances.

• A 510(k) is judged against a legally marketed predicate device, not against an absolute safety and effectiveness standard.
• The 90-day period is a statutory submission lead time, not a review completion commitment from the agency.
• No commercial distribution and no shipments to the United States may be arranged before the substantial equivalence letter is received.
• Payment of the applicable user fee is a prerequisite for acceptance of the submission and has no bearing whatsoever on the final decision.
• A finding of not substantially equivalent (NSE) places the device legally in Class III, requiring a PMA or a De Novo request under FD&C Act §513(f)(2).
• Predicate availability should drive pathway selection: a suitable predicate supports a 510(k), while its absence points toward De Novo or PMA.

2. Legal basis

The table below lists the principal statutory and regulatory authorities governing the 510(k) pathway, together with the key propositions each source supports. All entries were verified against the electronic Code of Federal Regulations and FDA official website content in 2026.

3. Expert insights

Insight 1: The 510(k) standard is comparative, not absolute. Under FD&C Act §513(i), the substantial equivalence determination rests on two questions. First, the device must have the same intended use as the predicate. Second, it must have the same technological characteristics, or different technological characteristics that do not raise different questions of safety and effectiveness. The information submitted must demonstrate that the device is as safe and effective as the predicate. This is a fundamentally different evidentiary standard from the PMA requirement of reasonable assurance of safety and effectiveness, and teams should never assume that evidence sufficient for one pathway will satisfy the other.

Insight 2: The phrase “at least 90 days” describes a submission obligation, not a review clock. The official FDA wording states that a 510(k) must be submitted at least 90 days before the sponsor intends to commercially distribute the device. This creates a submission duty; it does not promise that FDA will issue a decision within 90 days of receipt. The actual elapsed time is influenced by requests for Additional Information (AI) and by the number of interactive review cycles, which can extend the process well beyond the statutory lead time. Sponsors who treat the 90-day rule as a delivery guarantee routinely build schedules that cannot be met.

Insight 3: Payment and outcome are formally disconnected. FDA states explicitly that the payment of a premarket review fee is not related in any way to the final decision on a submission. The fee is a condition of acceptance for review, never consideration for approval. Budgeting and internal communications should reflect this distinction so that fee payment is never presented internally as a step toward clearance.

Insight 4: An NSE finding is a pathway escalation, not merely a rejection. A device for which substantial equivalence is not granted falls legally into Class III, and the sponsor must then pursue a PMA or submit a De Novo request under FD&C Act §513(f)(2). Because this escalation changes cost, timeline, and evidence requirements dramatically, the availability of a suitable predicate should be evaluated before the pathway is chosen, not after an NSE letter arrives.

Taken together, these four points frame the 510(k) as a pathway whose logic is anchored in comparison. The sponsor’s dossier must therefore be organized around the predicate: its identity, its K number, its intended use, and its technological profile. Every performance claim in the submission should trace back to the comparison table rather than to free-standing assertions of safety and effectiveness. Teams that internalize this comparative logic early tend to prepare dossiers that survive review with fewer Additional Information cycles, which in turn shortens the real elapsed time between submission and the substantial equivalence letter.

4. Practical recommendations

• Work backward from predicate availability when selecting the pathway: a suitable predicate supports a 510(k); without one, move to a De Novo or PMA assessment.
• Treat the 90-day period as the lower bound of the project schedule and reserve buffer time for Additional Information requests and interactive review cycles.
• Build the submission structure on the eSTAR template from the outset, so that late-stage rework of the dossier architecture is avoided.
• Do not schedule commercial distribution or shipments to the United States before the substantial equivalence letter has been received and filed.

5. Verification checklist

• □ Confirmed that a 510(k) must be submitted (the device is not exempt).
• □ Predicate device identified, with its K number and legal basis retained on file.
• □ Comparison analysis completed on the basis of the same intended use.
• □ Comparison analysis completed for technological characteristics: identical, or different without raising different questions of safety and effectiveness.
• □ Submission timing ensures filing at least 90 days before commercial distribution.
• □ Applicable MDUFA fee paid (unrelated to the outcome; a condition of acceptance only).

How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, US Agent and local testing support for the United States market. Our team manages FDA establishment registration and listing, 510(k)/De Novo/PMA submissions, and supports post-market reporting obligations. Business enquiries: info@grzanglobal.com